Nov 14 (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously that a GlaxoSmithKline Plc prototype vaccine against bird flu appears to be safe and produces the desired immune-system response against the highly fatal virus.
The London-based drugmaker said the advisory panel of outside medical experts voted 14 to 0 to support its vaccine against the H5N1 bird flu virus.
The virus is spread among birds but sometimes infects people, with highly fatal consequences.
"Glaxo looks forward to the approval by the FDA of our vaccine, hopefully later this year," said Leonard Friedland, a senior U.S. vaccine executive for the London-based drugmaker.
Friedland told Reuters there have been 608 cases of bird flu around the world since 2003, with 359 deaths.
If approved by the agency, Glaxo would be licensed to make millions of doses of the vaccine, which would likely be placed in a government stockpile for use in the event of a global epidemic.
The company would also be prepared to make as many other doses as required, perhaps including a slightly different strain of the virus than the Indonesia strain in its current prototype, Friedland said.